$ASTH earnings report

Astrana Health reported record revenue of $1,023.6 million, up 7% year-over-year, and record adjusted EBITDA of $77.2 million, up 13% year-over-year, for the three months ended September 30, 2026. AlphAI read Astrana Health's third quarter 2026 filing as solid.

third quarter 2026

AlphAI · Earnings readASTH · third quarter 2026 · ended September 30, 2026

Astrana Health reported record revenue of $1,023.6 million, up 7% year-over-year, and record adjusted EBITDA of $77.2 million, up 13% year-over-year, for the three months ended September 30, 2026.

✓Solid quarter

Third-quarter revenue, adjusted EBITDA, adjusted EPS, operating income, and net income attributable to Astrana all increased from the prior-year quarter. The company also provided fourth-quarter and narrowed full-year 2026 revenue, adjusted EBITDA, and free-cash-flow guidance.

Revenue
$1.02B
7% y/y
Care Partners, three months ended September 30, 2026
$969M
8% y/y
EPS · non-GAAP
$0.71
4% y/y
Three months ending December 31, 2026 and year ending December 31, 2026 outlook
Three months ending December 31, 2026: $939 million to $1,039 million; year ending December 31, 2026: $3,900 million to $4,000 million

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenue, three months ended September 30, 2026GAAP$1.02B–7%
Capitation and other revenue, net, three months ended September 30, 2026GAAP$1.02B––
Capitation, net, three months ended September 30, 2026GAAP$936.7M––
Risk pool settlements and incentives, three months ended September 30, 2026GAAP$24.32M––
Management fee income, three months ended September 30, 2026GAAP$14.11M––
Fee-for-service, net, three months ended September 30, 2026GAAP$35.12M––
Other revenue, three months ended September 30, 2026GAAP$13.40M––
Cost of services, excluding depreciation and amortization, three months ended September 30, 2026GAAP$900.1M––
General and administrative expenses, three months ended September 30, 2026GAAP$68.05M––
Depreciation and amortization, three months ended September 30, 2026GAAP$15.62M––
Total expenses, three months ended September 30, 2026GAAP$983.7M––
Income from operations, three months ended September 30, 2026GAAP$39.88M––
Net income, three months ended September 30, 2026GAAP$20.3M–1,782%
Net income attributable to Astrana Health, Inc., three months ended September 30, 2026GAAP$13M––
EPS - diluted, three months ended September 30, 2026GAAP$0.26––
Adjusted EBITDA, three months ended September 30, 2026non-GAAP$77.2M–13%
Adjusted EBITDA margin, three months ended September 30, 2026non-GAAP8%––
Adjusted EPS - diluted, three months ended September 30, 2026non-GAAP$0.71–4%
Total revenue, nine months ended September 30, 2026GAAP$2.96B–33%
Capitation and other revenue, net, nine months ended September 30, 2026GAAP$2.96B––
Capitation, net, nine months ended September 30, 2026GAAP$2.74B––
Risk pool settlements and incentives, nine months ended September 30, 2026GAAP$58.63M––
Management fee income, nine months ended September 30, 2026GAAP$43.00M––
Fee-for-service, net, nine months ended September 30, 2026GAAP$95.94M––
Other revenue, nine months ended September 30, 2026GAAP$28.3M––
Income from operations, nine months ended September 30, 2026GAAP$102.7M––
Net income attributable to Astrana Health, Inc., nine months ended September 30, 2026GAAP$47.1M–186%
EPS - diluted, nine months ended September 30, 2026GAAP$0.95–188%
Adjusted EBITDA, nine months ended September 30, 2026non-GAAP$212.4M–39%
Adjusted EBITDA margin, nine months ended September 30, 2026non-GAAP7%––
Adjusted EPS - diluted, nine months ended September 30, 2026non-GAAP$2.25–36%
Net cash provided by operating activities, nine months ended September 30, 2026GAAP$117.1M––
Free cash flow, nine months ended September 30, 2026non-GAAP$105.4M––

Segments

SegmentRevenueq/qy/y
Care Partners, three months ended September 30, 2026Not separately stated in the filing.$968.8M–8%
Care Delivery, three months ended September 30, 2026Not separately stated in the filing.$91.02M–5%
Care Enablement, three months ended September 30, 2026Not separately stated in the filing.$92.00M–5%
Care Partners, nine months ended September 30, 2026Not separately stated in the filing.$2.81B–32%

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Three months ending December 31, 2026 and year ending December 31, 2026 outlook

  • RevenueThree months ending December 31, 2026: $939 million to $1,039 million; year ending December 31, 2026: $3,900 million to $4,000 million
  • NoteAdjusted EBITDA, three months ending December 31, 2026: $48.5 million to $61.5 million
  • NoteAdjusted EBITDA, year ending December 31, 2026: $261 million to $274 million
  • NoteFree cash flow, year ending December 31, 2026: $107.5 million to $130 million
  • NoteNet income, three months ending December 31, 2026: $3.1 million to $9.1 million
  • NoteNet income, year ending December 31, 2026: $55.0 million to $61.0 million
  • NoteNet cash provided by operating activities, year ending December 31, 2026: $127.5 million to $142.5 million

Capital returns

  • Dividends paid, nine months ended September 30, 2026: $1,127 (in thousands)
  • Purchase of treasury shares, nine months ended September 30, 2026: $3,893 (in thousands)

What drove it

  • Care Partners revenue was $968,757 for the three months ended September 30, 2026, up 8% versus the prior-year quarter.
  • The company closed the acquisition of an independent practice association in Georgia on October 1, 2026.
  • Astrana added two Care Enablement clients, a provider group in Connecticut and a hospital in California, both expected to onboard in early 2027.
  • The company entered into several new Medicare Advantage payer partnerships effective January 1, 2027, including new health plan partners in Southern California, Texas, and Arizona.

Concerns

  • Care Delivery reported an income from operations loss of $1,591 (in thousands) for the three months ended September 30, 2026.
  • Net cash provided by operating activities was $117,077 (in thousands) for the nine months ended September 30, 2026, compared with $117,484 (in thousands) for the prior-year period.
  • Free cash flow was $105,366 (in thousands) for the nine months ended September 30, 2026, compared with $110,442 (in thousands) for the prior-year period.
  • The forward-looking statements identify a material weakness in internal control over financial reporting and the company's ability to remediate it in a timely manner as a risk.

What to watch

  • Delivery against fourth-quarter 2026 revenue guidance of $939 million to $1,039 million and adjusted EBITDA guidance of $48.5 million to $61.5 million.
  • Delivery against full-year 2026 revenue guidance of $3,900 million to $4,000 million, adjusted EBITDA guidance of $261 million to $274 million, and free-cash-flow guidance of $107.5 million to $130 million.
  • Onboarding of the two Care Enablement clients expected in early 2027.
  • Implementation of the new Medicare Advantage payer partnerships effective January 1, 2027.
  • Performance of Care Delivery, which reported income from operations of $(1,591) (in thousands) in the third quarter.

Balance sheet and cash flow

  • Cash and cash equivalents as of September 30, 2026: $396,225 (in thousands); December 31, 2025: $429,474 (in thousands)
  • Total debt as of September 30, 2026: current portion of long-term debt of $59,831 (in thousands) and long-term debt, net of current portion and deferred financing costs, of $865,546 (in thousands)
  • Total assets as of September 30, 2026: $2,343,432 (in thousands); December 31, 2025: $2,218,661 (in thousands)
  • Total liabilities as of September 30, 2026: $1,711,931 (in thousands); December 31, 2025: $1,660,327 (in thousands)
  • Purchases of property and equipment, nine months ended September 30, 2026: $11,711 (in thousands); nine months ended September 30, 2025: $7,042 (in thousands)
  • Net cash used in investing activities, nine months ended September 30, 2026: $14,870 (in thousands); nine months ended September 30, 2025: $537,942 (in thousands)
  • Net cash used in financing activities, nine months ended September 30, 2026: $135,060 (in thousands); net cash provided by financing activities for the nine months ended September 30, 2025: $595,683 (in thousands)

Analysis

Astrana reported record third-quarter revenue of $1,023.6 million, up 7% from $956.0 million, alongside adjusted EBITDA of $77.2 million, up 13% from $68.5 million. GAAP net income was $20.3 million versus $1.1 million, while net income attributable to Astrana was $13.0 million versus $0.4 million. Diluted EPS was $0.26 compared with $0.01, and adjusted diluted EPS rose to $0.71 from $0.68.

Care Partners was the largest reported segment at $968,757 (in thousands) of third-quarter revenue and grew 8%. Care Delivery revenue was $91,017 (in thousands), up 5%, while Care Enablement revenue was $92,001 (in thousands), also up 5%. Care Delivery recorded an operating loss of $1,591 (in thousands), whereas Care Partners generated income from operations of $49,093 (in thousands) and Care Enablement generated $24,435 (in thousands).

The nine-month period showed faster growth than the third quarter, with total revenue of $2,961.2 million, up 33%, and adjusted EBITDA of $212.4 million, up 39%. Nine-month net cash provided by operating activities was $117.1 million and free cash flow was $105.4 million, compared with $117.5 million and $110.4 million, respectively, in the prior-year period. Cash and cash equivalents were $396,225 (in thousands) at September 30, 2026, while current and non-current long-term debt were $59,831 (in thousands) and $865,546 (in thousands), respectively.

The company is guiding for fourth-quarter revenue of $939 million to $1,039 million and adjusted EBITDA of $48.5 million to $61.5 million. Full-year 2026 guidance was narrowed to revenue of $3,900 million to $4,000 million, adjusted EBITDA of $261 million to $274 million, and free cash flow of $107.5 million to $130 million. Operating developments include a Georgia acquisition closed on October 1, 2026, two Care Enablement clients expected to onboard in early 2027, and Medicare Advantage payer partnerships effective January 1, 2027.

Revenue composition included higher capitation, net, management fee income, and other revenue in the third quarter, while risk pool settlements and incentives and fee-for-service revenue were lower than the prior-year quarter. Adjusted EBITDA margin was reported at 8% in the third quarter versus 7% in the prior-year quarter. The filing also identifies a material weakness in internal control over financial reporting and the ability to remediate it in a timely manner among its forward-looking risks.

Management, verbatim

Our third quarter results demonstrate the growing impact of Astrana’s physician-centric, AI-native healthcare operating platform and our team’s continued focus on execution.

Brandon Sim, President and Chief Executive Officer of Astrana Health

Not in the filing

stated, not guessed
  • Prior-quarter comparisons were not reported for the presented financial metrics.
  • GAAP gross profit and GAAP gross margin were not reported.
  • A prior-outlook section was not provided, so comparison of actual results with prior guidance is unavailable.
  • Guidance for gross margin, operating expenses, and tax rate was not provided.
  • A detailed driver for each reported segment's revenue change was not separately stated.
  • Share repurchases were not separately reported; the cash flow statement reports purchase of treasury shares.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about ASTH earnings dates

When is Astrana Health's next earnings date?
AlphAI has no date for ASTH yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.